NewAmsterdam Pharma (NAMS) News Today $24.90 -0.07 (-0.28%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period RA Capital Management, L.P. Expands Stake in NewAmsterdam Pharma Co NVNovember 15 at 8:01 AM | gurufocus.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Bought by GSA Capital Partners LLPGSA Capital Partners LLP lifted its position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 79.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 66,402 shares of the company's stock after purchaNovember 15 at 4:36 AM | marketbeat.comIs NewAmsterdam Pharma (NAMS) Top Performing European Stock Heading into 2025?November 14 at 3:51 PM | msn.comOptimistic Buy Rating for NewAmsterdam Pharma Driven by Promising Clinical Trials and Innovative Lipid-Lowering TherapiesNovember 12, 2024 | markets.businessinsider.comNewAmsterdam Pharma Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)November 12, 2024 | benzinga.comLisanti Capital Growth LLC Invests $700,000 in NewAmsterdam Pharma (NASDAQ:NAMS)Lisanti Capital Growth LLC acquired a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 42,165 shares of the company's stock, valued at approximately $700,000. Several other institutiNovember 12, 2024 | marketbeat.comQ4 EPS Estimate for NewAmsterdam Pharma Reduced by AnalystNovember 12, 2024 | americanbankingnews.comResearch Analysts Set Expectations for NAMS FY2024 EarningsNovember 12, 2024 | americanbankingnews.comNewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Shares Could Be 46% Below Their Intrinsic Value EstimateNovember 11, 2024 | finance.yahoo.comQ4 EPS Forecast for NewAmsterdam Pharma Reduced by AnalystNewAmsterdam Pharma (NASDAQ:NAMS - Free Report) - Equities researchers at William Blair dropped their Q4 2024 earnings per share (EPS) estimates for NewAmsterdam Pharma in a research report issued to clients and investors on Wednesday, November 6th. William Blair analyst M. Phipps now anticipatesNovember 11, 2024 | marketbeat.comEquities Analysts Offer Predictions for NAMS FY2024 EarningsNewAmsterdam Pharma (NASDAQ:NAMS - Free Report) - Equities research analysts at Leerink Partnrs upped their FY2024 earnings per share (EPS) estimates for NewAmsterdam Pharma in a research note issued on Wednesday, November 6th. Leerink Partnrs analyst R. Ruiz now expects that the company will earNovember 11, 2024 | marketbeat.comLeerink Partnrs Has Strong Estimate for NAMS FY2028 EarningsNovember 10, 2024 | americanbankingnews.comBrokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) Target Price at $33.80November 9, 2024 | americanbankingnews.comNewAmsterdam Pharma’s Promising Clinical Progress and Solid Financial Position Drive Buy RatingNovember 8, 2024 | markets.businessinsider.comNewAmsterdam Pharma Reports Strong Q3 and Trial ProgressNovember 8, 2024 | markets.businessinsider.comNewAmsterdam Pharma Reports Strong Q3 and Trial ProgressNovember 8, 2024 | markets.businessinsider.comLeerink Partnrs Has Strong Forecast for NAMS FY2028 EarningsNewAmsterdam Pharma (NASDAQ:NAMS - Free Report) - Analysts at Leerink Partnrs raised their FY2028 earnings estimates for NewAmsterdam Pharma in a report released on Wednesday, November 6th. Leerink Partnrs analyst R. Ruiz now anticipates that the company will earn $0.44 per share for the year, upNovember 8, 2024 | marketbeat.comNewamsterdam Pharma Faces Compliance Cost Surge as Emerging Growth Status EndsNovember 8, 2024 | markets.businessinsider.comWhat 4 Analyst Ratings Have To Say About NewAmsterdam PharmaNovember 7, 2024 | benzinga.comNeedham & Company LLC Reaffirms "Buy" Rating for NewAmsterdam Pharma (NASDAQ:NAMS)Needham & Company LLC reaffirmed a "buy" rating and set a $36.00 price target on shares of NewAmsterdam Pharma in a research report on Thursday.November 7, 2024 | marketbeat.comNewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial ResultsNovember 6, 2024 | markets.businessinsider.comNewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial ResultsNovember 6, 2024 | markets.businessinsider.comNewAmsterdam Pharma (NASDAQ:NAMS) Given Average Recommendation of "Buy" by BrokeragesNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) has earned a consensus recommendation of "Buy" from the seven ratings firms that are currently covering the firm, Marketbeat reports. Seven equities research analysts have rated the stock with a buy rating. The average 1 year price target among bNovember 6, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Acquired by abrdn plcabrdn plc raised its position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 69.8% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 129,060 shares of the company's stock after purchasing an additional 53,06November 5, 2024 | marketbeat.comNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 1, 2024 | globenewswire.comNewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in NovemberOctober 28, 2024 | globenewswire.comNewAmsterdam Pharma (NASDAQ:NAMS) Given Average Rating of "Buy" by BrokeragesShares of NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) have earned a consensus rating of "Buy" from the seven ratings firms that are presently covering the company, Marketbeat.com reports. Seven research analysts have rated the stock with a buy recommendation. The average twelve-month priceOctober 12, 2024 | marketbeat.comMarshall Wace LLP Reduces Holdings in NewAmsterdam Pharma (NASDAQ:NAMS)Marshall Wace LLP lowered its position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 81.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 21,831 shares of the company's stock after selling 93,549 shares durinOctober 11, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Bought by Millennium Management LLCMillennium Management LLC lifted its stake in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 23.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,165,429 shares of the companOctober 5, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Stock, Short Interest ReportOctober 5, 2024 | benzinga.comNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 4, 2024 | globenewswire.comInsider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells 45,000 Shares of StockOctober 2, 2024 | insidertrades.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Down to $16.60NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Down to $16.60October 1, 2024 | marketbeat.comJuliette Berangere Audet Purchases 1,104 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) StockOctober 1, 2024 | insidertrades.comDeerfield Management Company L.P. Series C Acquires 202,250 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)Deerfield Management Company L.P. Series C grew its holdings in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 30.3% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 869,250 shares of the company's stock after buying aSeptember 26, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Purchased by Affinity Asset Advisors LLCAffinity Asset Advisors LLC boosted its stake in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 47.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 423,155 shares of the company's stock after buying an addiSeptember 25, 2024 | marketbeat.comNewAmsterdam Pharma Company N.V. (KH6.F)September 24, 2024 | nz.finance.yahoo.comPiper Sandler Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)September 24, 2024 | markets.businessinsider.comNovo Nordisk shares drop nearly 5% on disappointing obesity pill dataSeptember 22, 2024 | msn.comWhile institutions own 29% of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), private equity firms are its largest shareholders with 47% ownershipSeptember 7, 2024 | finance.yahoo.comNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 6, 2024 | globenewswire.comRoyal Bank of Canada Reiterates Outperform Rating for NewAmsterdam Pharma (NASDAQ:NAMS)Royal Bank of Canada reiterated an "outperform" rating and set a $31.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday.September 5, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Short Interest UpdateNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) was the target of a significant increase in short interest in August. As of August 15th, there was short interest totalling 1,690,000 shares, an increase of 20.7% from the July 31st total of 1,400,000 shares. Currently, 4.3% of the company's stock are sold short. Based on an average trading volume of 319,500 shares, the days-to-cover ratio is presently 5.3 days.September 1, 2024 | marketbeat.comNewAmsterdam Pharma to Participate in Upcoming Investor Conferences in SeptemberAugust 30, 2024 | globenewswire.comNeedham Initiates Coverage of NewAmsterdam Pharma Company N.V. (NAMS) with Buy RecommendationAugust 29, 2024 | msn.comNewAmsterdam Pharma (NASDAQ:NAMS) Stock Quotes, Forecast and News SummaryAugust 29, 2024 | benzinga.comBuy Rating Affirmed for NewAmsterdam Pharma on Strong Prospects for Cholesterol Drug obicetrapibAugust 28, 2024 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)August 28, 2024 | markets.businessinsider.comNewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive UpsideAugust 28, 2024 | finance.yahoo.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Up to $16.77NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Up to $16.77August 28, 2024 | marketbeat.com Get NewAmsterdam Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter. Email Address 2024's Must-Watch Stocks! (Ad)Welcome to a year of unparalleled opportunities! Dive into our exclusive guide, "9 Stocks Set to Soar," meticulously selected to elevate your portfolio in 2024. Step into 2024 with confidence and the right assets at your fingertips. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time. [Unlock Your Report Now] NAMS Media Mentions By Week NAMS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NAMS News Sentiment▼0.570.55▲Average Medical News Sentiment NAMS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NAMS Articles This Week▼213▲NAMS Articles Average Week Get NewAmsterdam Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Elanco Animal Health News Blueprint Medicines News Cytokinetics News Nuvalent News Krystal Biotech News Avidity Biosciences News Biohaven News Ultragenyx Pharmaceutical News BridgeBio Pharma News Arcellx News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NAMS) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
